Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,847 Mln
P/E Ratio
26.93
P/B Ratio
14.94
Industry P/E
--
Debt to Equity
0.24
ROE
0.82 %
ROCE
55.86 %
Div. Yield
0 %
Book Value
1.42
EPS
0.8
CFO
$-489.62 Mln
EBITDA
$-313.04 Mln
Net Profit
$-506.33 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
| 40.58 | 19.00 | 49.10 | 268.09 | 133.66 | 52.43 | 10.98 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
| 275.32 | 16.49 | 175.18 | -27.69 | -51.25 | 67.36 | -25.43 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.42 | 6,839.20 | -- | 38.11 | |
| 73.23 | 7,493.81 | 57.68 | 23.56 | |
| 60.43 | 11,518.55 | 396.8 | 0.76 | |
| 8.34 | 9,847.94 | -- | -3.24 |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers... BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446 Read more
Co-Founder, President, CEO & Director
Mr. Adam S. Grossman
Co-Founder, President, CEO & Director
Mr. Adam S. Grossman
Headquarters
Ramsey, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ADMA Biologics Inc (ADMA) stood at $ 489 Mln as on 31-Dec-24
The share price of ADMA Biologics Inc (ADMA) is $24.11 (NASDAQ) as of 29-Apr-2025 16:29 EDT. ADMA Biologics Inc (ADMA) has given a return of 133.66% in the last 3 years.
ADMA Biologics Inc (ADMA) has a market capitalisation of $ 5,847 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of ADMA Biologics Inc (ADMA) is 26.93 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ADMA Biologics Inc (ADMA) and enter the required number of quantities and click on buy to purchase the shares of ADMA Biologics Inc (ADMA).
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446
The CEO & director of Mr. Adam S. Grossman. is ADMA Biologics Inc (ADMA), and CFO & Sr. VP is Mr. Adam S. Grossman.
There is no promoter pledging in ADMA Biologics Inc (ADMA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| ADMA Biologics Inc (ADMA) | Ratios |
|---|---|
|
Return on equity(%)
|
81.65
|
|
Operating margin(%)
|
32.75
|
|
Net Margin(%)
|
46.35
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ADMA Biologics Inc (ADMA) was $0 Mln.
$-0.40
(
